Search
Tango Therapeutics Inc
TNGXAdd to Watchlist
21.750USD
-1.740-7.41%
Close 09-18 16:00（ET）
3.66BMarket Cap
LossP/E TTM
Tango Therapeutics Inc (TNGX) Stock Price Target & Forecast
Analyst Rating
Based on 13 analysts giving stock ratings to Tango Therapeutics Inc in the past month.
Buy
6 Strong Buy
6 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
45.100USD+92.00%
TNGX Analyst Recommendation Trends
In the current month, TNGX has received 6 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. TNGX average Analyst price target in the last month is 45.100.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
6
6
5
5
5
5
5
4
6
6
6
5
5
4
4
4
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13
13
12
11
11
10
10
9
TNGX Analyst Rating for Peer Comparison
Updated: Sep 20, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Ascendis Pharma A/S
ASND
10
10
0
0
0
20
Financial Forecasting
Based on analysts' estimates, TNGX EPS is projected to reach -0.353 in FY2026Q3, following reported EPS of -0.369 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.32
-0.31
-0.32
-0.35
-0.38
Actual
-0.29
-0.32
-0.37
--
--
Surprise
+8.53%
-1.17%
-15.95%
--
--
FAQs
What is Tango Therapeutics Inc's price target?
Analysts forecast that Tango Therapeutics Inc's price target is USD 45.10, with the highest forecast at USD 69.00 and the lowest forecast at USD 24.00.
How have Tango Therapeutics IncTNGX's recent earnings per share performed?
The market expectation was USD -0.37, while Tango Therapeutics IncTNGX's earnings per share (EPS) for the previous quarter was USD -0.32. EPS for the next quarter is expected at USD -0.35.
What is the analyst rating for Tango Therapeutics Inc?
Based on the ratings of Tango Therapeutics Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.